Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire November 13, 2025 Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 […]

MediaAlpha Appoints Insurance Industry Veteran Ramon Jones to Board of Directors Former Nationwide CMO Brings Over 25 years of P&C Insurance and Digital Marketing Expertise GlobeNewswire November 13, 2025 LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) — MediaAlpha, Inc. (NYSE: MAX), the leading marketing technology platform powering real-time customer acquisition for the insurance industry, today

ORIC(R) Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates GlobeNewswire November 13, 2025 Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical

Union Calls for Hearing on Bill to Hold Amazon Accountable for Worker Abuse The Teamsters and their allies have reached a major milestone for working people as the Delivery Protection Act secured a bipartisan, veto-proofsupermajority of sponsors in the New York City Council. This legislation would hold Amazon accountable for its exploitative labor practices and

(TSX:FRX),(NASDAQ:FENC), RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares GlobeNewswire November 13, 2025 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition,

(NASDAQ:FLNT), • Q3 2025 revenue of $47.0 million; YTD 2025 revenue of $146.9 million • Q3 2025 Commerce Media Solutions revenue grew 81% to $18.8 million, representing 40% of consolidated revenue from $10.4 million or 16% of consolidated revenue in Q3 2024 • Commerce Media Solutions annual revenue run rate now exceeds $85 million, with

(NASDAQ:NDAQ), NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) will be presenting at the following conferences with webcasts available at Nasdaq's Investor Relations website: ir.nasdaq.com/events.cfm. Who: Sarah Youngwood, Executive Vice President and CFO, Nasdaq What: J.P. Morgan 2025 Ultimate Services Investor Conference When: Wednesday, November 18, 20252:00 PM ET Who: Sarah Youngwood,

(NASDAQ:HYPD), Management Initiates Q4'25 Adjusted Revenue(3) Guidance of 31% to 43% Q-o-Q Growth Over 13 Million HYPE Tokens Staked to Hyperion's Validator as of October 31, 2025 Ramping Business Lines Expected to Achieve Positive Operating Cash Flows in 2026 LAGUNA HILLS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi”

(TSX:PRN),(NASDAQ:PROF), TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in